2. Academic Validation
  3. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation

An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation

  • Bone. 2010 Feb;46(2):534-42. doi: 10.1016/j.bone.2009.09.028.
Sanjay Kumar 1,  Christopher J Matheny,  Sandra J Hoffman,  Robert W Marquis,  Maggie Schultz,  Xiaoguang Liang,  Janice A Vasko,  George B Stroup,  Vernal R Vaden,  Hyking Haley,  John Fox,  Eric G DelMar,  Edward F Nemeth,  Amparo M Lago,  James F Callahan,  Pradip Bhatnagar,  William F Huffman,  Maxine Gowen,  Bingming Yi,  Theodore M Danoff,  Lorraine A Fitzpatrick
Affiliations

Affiliation

  • 1 GlaxoSmithKline, UM 2230, 709 Swedeland Road, King of Prussia, PA 19406-2711, USA.
PMID: 19786130 DOI: 10.1016/j.bone.2009.09.028
Abstract

Daily subcutaneous administration of exogenous parathyroid hormone (PTH) promotes bone formation in patients with osteoporosis. Here we describe two novel, short-acting calcium-sensing receptor antagonists (SB-423562 and its orally bioavailable precursor, SB-423557) that elicit transient PTH release from the parathyroid gland in several preclinical species and in humans. In an ovariectomized rat model of bone loss, daily oral administration of SB-423557 promoted bone formation and improved parameters of bone strength at lumbar spine, proximal tibia and midshaft femur. Chronic administration of SB-423557 did not increase parathyroid cell proliferation in rats. In healthy human volunteers, single doses of intravenous SB-423562 and oral SB-423557 elicited transient elevations of endogenous PTH concentrations in a profile similar to that observed with subcutaneously administered PTH. Both agents were well tolerated in humans. Transient increases in serum calcium, an expected effect of increased parathyroid hormone concentrations, were observed post-dose at the higher doses of SB-423557 studied. These data constitute an early proof of principle in humans and provide the basis for further development of this class of compound as a novel, orally administered bone-forming treatment for osteoporosis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z